As of Apr 24
| -0.64 / -1.34%|
The 19 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 44.88, with a high estimate of 58.25 and a low estimate of 38.98. The median estimate represents a -4.93% decrease from the last price of 47.21.
The current consensus among 19 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.